ANALISA DRUG RELATED PROBLEM PADA ENDOMETRIOSIS DI PUSKESMAS DUREN SERIBU PERIODE 1 JANUARI - 30 JUNI 2025
DOI:
https://doi.org/10.62619/jptb.v5i2.276Keywords:
Drug-Related Problem, Endometriosis, Hormone Therapy, Combination Oral ContraceptivesAbstract
This study analyzed the incidence of drug-related problems, including adverse events and medical errors, and possible associated risk factors, in patients with endometriosis who used combined oral contraceptives (COCs) and progestins. Reports were collected between January 1, 2024, and June 30, 2025, regarding endometriosis patients in the Medical Record System at the Duren Seribu Community Health Center, Depok City. A disproportionate analysis was performed using the Gamma–Poisson Shrinker model to detect overreported drug–event pairs. Logistic regression analysis was used to explore potential risk factors. There were 23 reports regarding long-term hormonal treatment and 45 reports regarding other medications used for endometriosis. Long-term hormonal treatment included: 15 reports (22.0%) of combined oral contraceptives (COCs), 10 reports (14.7%) of oral progestins, 8 reports (11.76%) of injectable (depot) progestins, 23 reports (33.82%) of progestin-releasing IUDs, and 12 reports (17.64%) of progestin-only implants. Both combined oral contraceptives (COCs) and progestin-only products are relatively safe for patients with endometriosis. Combination therapy (polytherapy) has been negatively associated with several medical errors in COC users, while patients aged ≥30 years have had more pulmonary embolism cases but fewer reported product-related problems.
Downloads
References
Armstrong C. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115(1):206–218.
doi:10.1097/AOG.0b013e3181cb50b5
Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107(3):555–565.
doi:10.1016/j.fertnstert.2016.12.025
Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107(3):537–548. doi:10.1016/j.fertnstert.2016.12.024
Brichant G, Laraki I, Henry L, Munaut C, Nisolle M. New therapeutics in endometriosis: a review of hormonal, non-hormonal, and non-coding RNA treatments. Int J Mol Sci. 2021;22(19):10498. doi:10.3390/ijms221910498
Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–650. doi:10.1093/ humupd/dmq022
Committee of the American Society for Reproductive M. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107(1):43–51. doi:10.1016/j.fertnstert.2016.09.027asi. (Hendra Teguh & Ronny Antonius Rusli, Trans.). Jakarta: Prenhallindo.
Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–536. doi:10.1016/j.fertnstert.2017.01.003
Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): a systematic review. Contraception. 2016;94(3):202–215. doi:10.1016/j.contraception.2016.02.003
Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal college of general practitioners’ oral contraception study. BMJ. 2010;340:c927. doi:10.1136/bmj.c927
Habib N, Buzzaccarini G, Centini G, et al. Impact of lifestyle and diet on endometriosis: a fresh look to a busy corner. Prz Menopauzalny. 2022;21 (1):124–132.
Mechsner S. Endometriosis, an ongoing pain-step-by-step treatment. J Clin Med. 2022;11(2):467. doi:10.3390/jcm11020467
Mehdizadeh Kashi A, Niakan G, Ebrahimpour M, et al. A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis. Int J Gynaecol Obstet. 2022;156(1):124–132. doi:10.1002/ ijgo.13677
Matalliotakis I, Cakmak H, Matalliotakis M, Kappou D, Arici A. High rate of allergies among women with endometriosis. J Obstet Gynaecol.2012;32(3):291–293. doi:10.3109/01443615.2011.644358sics/hierarchy. Accessed May 2, 2022.
Mishell DR Jr., Kletzky OA, Brenner PF, Roy S, Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obstet Gynecol. 1977;128(1):60–74. doi:10.1016/0002-9378(77)90295-2
Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–1076. doi:10.1111/j.1447-0756.2009.01076.x
Pfeifer S, Butts S, Dumesic D, Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, Practice
Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. doi:10.1136/bmj.m441
Sharma SC, Basu NN. Galactorrhea/Galactocele after breast augmentation: a systematic review. Ann Plast Surg. 2021;86(1):115–120.doi:10.1097/ SAP.0000000000002290
Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106(6):1289–1294. doi:10.1016/j.fertnstert.2016.08.039
TmotEGC G, Becker CM, Bokor A, et al. ESHRE guideline: endometriosis. Human Reproduction Open. 2022. doi:10.1093/hropen/hoac009
Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod. 2011;26(1):3–13. doi:10.1093/humrep/deq302
Vercellini P, Ottolini F, Frattaruolo MP, Buggio L, Roberto A, Somigliana E. Shifting from oral contraceptives to norethisterone acetate, or vice versa, because of drug intolerance: does the change Benefit women with endometriosis? Gynecol Obstet Invest. 2018;83(3):275–284. doi:10.1159/ 000486335
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rahayu Mustika Sari, Niati Ambarsari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
